307 related articles for article (PubMed ID: 19010455)
1. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts.
Jilka RL; O'Brien CA; Ali AA; Roberson PK; Weinstein RS; Manolagas SC
Bone; 2009 Feb; 44(2):275-86. PubMed ID: 19010455
[TBL] [Abstract][Full Text] [Related]
2. Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration.
Ogita M; Rached MT; Dworakowski E; Bilezikian JP; Kousteni S
Endocrinology; 2008 Nov; 149(11):5713-23. PubMed ID: 18617606
[TBL] [Abstract][Full Text] [Related]
3. Intermittent PTH treatment can delay the transformation of mature osteoblasts into lining cells on the periosteal surfaces.
Jang MG; Lee JY; Yang JY; Park H; Kim JH; Kim JE; Shin CS; Kim SY; Kim SW
J Bone Miner Metab; 2016 Sep; 34(5):532-9. PubMed ID: 26303221
[TBL] [Abstract][Full Text] [Related]
4. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.
Jilka RL
Bone; 2007 Jun; 40(6):1434-46. PubMed ID: 17517365
[TBL] [Abstract][Full Text] [Related]
5. Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts.
Kim SW; Pajevic PD; Selig M; Barry KJ; Yang JY; Shin CS; Baek WY; Kim JE; Kronenberg HM
J Bone Miner Res; 2012 Oct; 27(10):2075-84. PubMed ID: 22623172
[TBL] [Abstract][Full Text] [Related]
6. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
[TBL] [Abstract][Full Text] [Related]
7. Aging periosteal progenitor cells have reduced regenerative responsiveness to bone injury and to the anabolic actions of PTH 1-34 treatment.
Yukata K; Xie C; Li TF; Takahata M; Hoak D; Kondabolu S; Zhang X; Awad HA; Schwarz EM; Beck CA; Jonason JH; O'Keefe RJ
Bone; 2014 May; 62():79-89. PubMed ID: 24530870
[TBL] [Abstract][Full Text] [Related]
8. Progenitor recruitment and adipogenic lipolysis contribute to the anabolic actions of parathyroid hormone on the skeleton.
Maridas DE; Rendina-Ruedy E; Helderman RC; DeMambro VE; Brooks D; Guntur AR; Lanske B; Bouxsein ML; Rosen CJ
FASEB J; 2019 Feb; 33(2):2885-2898. PubMed ID: 30354669
[TBL] [Abstract][Full Text] [Related]
9. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
Ominsky MS; Brown DL; Van G; Cordover D; Pacheco E; Frazier E; Cherepow L; Higgins-Garn M; Aguirre JI; Wronski TJ; Stolina M; Zhou L; Pyrah I; Boyce RW
Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
[TBL] [Abstract][Full Text] [Related]
10. Human parathyroid hormone-(1-34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats.
Liu CC; Kalu DN
J Bone Miner Res; 1990 Sep; 5(9):973-82. PubMed ID: 2281827
[TBL] [Abstract][Full Text] [Related]
11. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.
Jilka RL; O'Brien CA; Bartell SM; Weinstein RS; Manolagas SC
J Bone Miner Res; 2010 Nov; 25(11):2427-37. PubMed ID: 20533302
[TBL] [Abstract][Full Text] [Related]
12. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
[TBL] [Abstract][Full Text] [Related]
13. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
[TBL] [Abstract][Full Text] [Related]
14. The cell biology of parathyroid hormone in osteoblasts.
Kousteni S; Bilezikian JP
Curr Osteoporos Rep; 2008 Jun; 6(2):72-6. PubMed ID: 18778567
[TBL] [Abstract][Full Text] [Related]
15. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
[TBL] [Abstract][Full Text] [Related]
16. Osteopontin deficiency induces parathyroid hormone enhancement of cortical bone formation.
Kitahara K; Ishijima M; Rittling SR; Tsuji K; Kurosawa H; Nifuji A; Denhardt DT; Noda M
Endocrinology; 2003 May; 144(5):2132-40. PubMed ID: 12697722
[TBL] [Abstract][Full Text] [Related]
17. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
18. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells.
Dobnig H; Turner RT
Endocrinology; 1995 Aug; 136(8):3632-8. PubMed ID: 7628403
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of TIMP-1 in osteoblasts increases the anabolic response to PTH.
Merciris D; Schiltz C; Legoupil N; Marty-Morieux C; de Vernejoul MC; Geoffroy V
Bone; 2007 Jan; 40(1):75-83. PubMed ID: 16949899
[TBL] [Abstract][Full Text] [Related]
20. Anabolic action of parathyroid hormone (PTH) does not compromise bone matrix mineral composition or maturation.
Vrahnas C; Pearson TA; Brunt AR; Forwood MR; Bambery KR; Tobin MJ; Martin TJ; Sims NA
Bone; 2016 Dec; 93():146-154. PubMed ID: 27686599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
